Clinical trials: Moxifloxacin
Brucellosis, Osteoarthritis
Efficacy & Safety of Fluoroquinolone-Based Brucellosis Regimens (BRUCE)
Brucellosis is a globally distributed zoonosis with persistent clinical management challenges. The World Health Organization(WHO)-recommended doxycycline-rifampin (DOX-RIF) dual regimen may drive rifampin-associated antimicrobial…
- Trial name
- BRUCE (NCT07779629)
- Testing
- Doxycycline + Rifampicin, Doxycycline + Levofloxacin, Doxycycline + Moxifloxacin
- Where
- China
- Sponsor
- The First Affiliated Hospital of Shihezi University
Rifampicin-Resistant Pulmonary Tuberculosis, Multidrug-Resistant Pulmonary Tuberculosis
A Study of Quabodepistat-containing Regimens for the Treatment of Drug-resistant Pulmonary Tuberculosis
This is a Phase 3, randomized, open-label, active-controlled, multicenter trial evaluating the efficacy, safety, and tolerability of quabodepistat-containing regimens for the treatment of rifampicin-resistant or…
- Trial name
- QUANTUM-TB (NCT07209761)
- Testing
- Bedaquiline, Quabodepistat, Pretomanid
- Where
- 42 sites in China, Georgia and 8 more
- Volunteers
- 532 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Basic Science
A Study to Assess the Effect of Olpasiran on QT/QTc Intervals in Healthy Participants
The primary objective of the study is: To assess the effects of a single therapeutic and supratherapeutic dose of olpasiran on the placebo-corrected change from baseline in QT corrected for heart rate (ΔΔQT)/QTc interval in…
- Trial name
- NCT06411860
- Testing
- Olpasiran, Moxifloxacin
- Where
- United Kingdom
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Amgen
Brucellosis
Fluoroquinolone-Doxycycline Oral Treatments for Adults With Uncomplicated Brucellosis
Brucellosis is a common zoonotic infectious disease. The standard dual regimen of doxycycline combined with rifampicin is widely used for uncomplicated brucellosis.
- Trial name
- BRUCE-U (NCT07887126)
- Testing
- Doxycycline + Rifampicin, Doxycycline + Levofloxacin, Doxycycline + Moxifloxacin
- Where
- 3 sites in China
- Volunteers
- 200 people
- Sponsor
- The First Affiliated Hospital of Shihezi University
Brucellosis, Osteoarticular Brucellosis
All-Oral Fluoroquinolone-Based Triple Therapies for Adults With Imaging-Confirmed Osteoarticular Brucellosis
Brucellosis is a globally distributed zoonosis with persistent clinical management challenges. The World Health Organization (WHO)-recommended doxycycline-rifampin (DOX-RIF) dual regimen may drive rifampin-associated…
- Trial name
- BRUCE-O (NCT07887152)
- Testing
- Doxycycline + Rifampicin + Ceftriaxone (intravenous therapy for 4 weeks), Triple oral regimen (Doxycycline + Rifampicin + Levofloxacin), Triple oral regimen (Doxycycline + Rifampicin + Moxifloxacin)
- Volunteers
- 150 people
- Sponsor
- The First Affiliated Hospital of Shihezi University
Odontogenic Infection, Maxillofacial Infection
Moxifloxacin Versus Clindamycin in the Management of Odontogenic Maxillofacial Infectious Processes
Investigators are conducting a trial to compare moxifloxacin against clindamycin for dental infections that spread to the face and jaw.
- Conditions
- Odontogenic Infection, Maxillofacial Infection, Cellulitis, Cellulitis of Face
- Trial name
- NCT07810244
- Testing
- Clindamycin, Moxifloxacin (400 mg)
- Where
- Pakistan
- Volunteers
- 60 people
- Sponsor
- Nishtar Medical University
Healthy Participants
A Single and Multiple Ascending Dose Study of EPX-100 in Healthy Adult Participants
A study to evaluate the safety and tolerability of single and multiple ascending doses of EPX-100 in healthy adult participants.
- Trial name
- NCT07879170
- Testing
- EPX-100, Moxifloxacin
- Where
- United States
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- Epygenix
Pulmonary Tuberculosis
Platform Assessing Regimens and Durations In a Global Multisite Consortium for TB
The UNITE4TB consortium is a group of universities and pharmaceutical companies funded by the European Union. This consortium are carrying out a trial to find better and faster ways to treat tuberculosis (TB).
- Trial name
- PARADIGM4TB (NCT06114628)
- Testing
- Ganfeborole, BTZ-043, Bedaquiline (B)
- Where
- 11 sites in Moldova, South Africa and 3 more
- Volunteers
- 2,500 people
- Sponsor
- University College, London
Tuberculosis, Pulmonary, Other Specified Pulmonary Tuberculosis
BTZ-043 Dose Evaluation in Combination and Selection
This is a phase 2B, open label study, that will compare the safety and efficacy of three experimental regimens consisting of bedaquiline and delamanid in combination with different doses of BTZ-043, a novel antibiotic, in adult…
- Trial name
- DECISION (NCT05926466)
- Testing
- BTZ-043, Bedaquiline, Delamanid
- Where
- 4 sites in South Africa, Tanzania
- Volunteers
- 92 people
- Sponsor
- Michael Hoelscher
HELICOBACTER PYLORI INFECTIONS
Efficacy and Safety of Second-Line Helicobacter Pylori Eradication
Subjects with persistent H. pylori infection after first-line treatment failure receives either a 14-day PPI-based moxifloxacin triple regimen (esomeprazole, amoxicillin, and moxifloxacin) or a 14-day P-CAB-bismuth-containing…
- Trial name
- NCT07855497
- Testing
- P-CAB-BM quadruple regimen, Moxifloxacin triple regimen
- Where
- South Korea
- Volunteers
- 141 people
- Sponsor
- Seoul National University Bundang Hospital
Cataract, Postoperative Endophthalmitis
Intracameral Levofloxacin Versus Moxifloxacin After Cataract Surgery
This randomized study aims to compare the safety and efficacy of intracameral levofloxacin versus intracameral moxifloxacin administered at the end of phacoemulsification cataract surgery.
- Trial name
- NCT07850414
- Testing
- Levofloxacin, Moxifloxacin
- Volunteers
- 93 people
- Sponsor
- Assiut University
Overweight, Obesity
Effect of Maridebart Cafraglutide on the Heart's Electrical Activity
The main objective of this trial is to evaluate the effect of maridebart cafraglutide subcutaneously (SC) on the placebo-corrected, change from baseline in QT interval corrected for heart rate using Fridericia's formula in…
- Trial name
- NCT07229157
- Testing
- Maridebart Cafraglutide, Moxifloxacin
- Where
- 2 sites in United States
- Volunteers
- 81 people
- Sponsor
- Amgen
Tuberculosis, Pulmonary, Tuberculosis Infection
Short-course Regimens for the Treatment of Pulmonary Tuberculosis
The purpose of this study is to determine whether one or two 17-week regimens of tuberculosis treatment bedaquiline (B or BDQ), moxifloxacin (M), pyrazinamide (Z)-- (BMZ) plus either Rifabutin (Rb) or Delamanid (D or DLM) are as…
- Trial name
- CRUSH-TB (NCT05766267)
- Testing
- Rifabutin, Delamanid, Bedaquiline
- Where
- 8 sites in United States, Canada and 4 more
- Volunteers
- 288 people
- Sponsor
- Centers for Disease Control and Prevention
Rhegmatogenous Retinal Detachment
Dropless Pars Plana Vitrectomy Study
To demonstrate that intraoperative use of subtenon triamcinolone acetonide at the time of surgery without postoperative eye drops is non-inferior to the regimen of postoperative eye drops following primary pars plana vitrectomy…
- Trial name
- DVS (NCT05331664)
- Testing
- Pars plana vitrectomy, Triamcinolone Acetonide 40mg/mL, Moxifloxacin 0.5% or Polymyxin/Trimethoprim if patient is allergic to moxifloxacin
- Where
- United States
- Volunteers
- 168 people, healthy volunteers welcome
- Sponsor
- Massachusetts Eye and Ear Infirmary
Tuberculosis, Pulmonary
Four Months Moxifloxacin Containing Daily Regimen Study Among New Pulmonary Tuberculosis Patients
The 4-month daily regimen containing moxifloxacin (2HRZEM 7 / 2HRM7) of ICMR-NIRT was studied in 321 sputum positive pulmonary TB patients in a randomised clinical trial.
- Trial name
- NCT05047055
- Testing
- Isoniazid, Rifampicin, Pyrazinamide
- Where
- India
- Volunteers
- 550 people
- Sponsor
- Tuberculosis Research Centre, India
Endophthalmitis
Safety and Efficacy of Intracameral Zimoxin for Prevention of Endophthalmitis After Cataract Surgery
Intracameral injection of 0.1% moxifloxacin solution after cataract surgery to prevent endophthalmitis
- Trial name
- NCT03244072
- Testing
- Moxifloxacin
- Where
- United States
- Volunteers
- 60,000 people, healthy volunteers welcome
- Sponsor
- Jason Ahee, M.D.
Bacterial Keratitis, Recalcitrant Infectious Keratitis
Intrastromal Moxifloxacin as an Adjunctive Therapy in Recalcitrant Bacterial Keratitis
Bacterial keratitis is a potentially sight-threatening corneal infection that is commonly treated with intensive topical antibiotics.
- Conditions
- Bacterial Keratitis, Recalcitrant Infectious Keratitis, Corneal Ulcer
- Trial name
- NCT07394257
- Testing
- Intrastromal moxifloxacin injection plus standard topical moxifloxacin therapy, Standard topical moxifloxacin therapy alone
- Where
- Egypt
- Volunteers
- 60 people
- Sponsor
- Minia University
COPD
A Phase I Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics for a Single Dose of HRS-9821 Powder for Inhalation and Inhalation Suspension Administered in Healthy Subjects and Multiple Doses in Patients With COPD.
The aim of this study was to evaluate the safety and tolerability of HRS-9821 Powder for Inhalation and inhalation suspension administered in a single dose in healthy individuals and multiple doses in patients with COPD
- Trial name
- NCT07116915
- Testing
- HRS-9821 Powder for Inhalation/HRS-9821 inhalation suspension, Moxifloxacin Hydrochloride Tablets
- Where
- China
- Volunteers
- 85 people, healthy volunteers welcome
- Sponsor
- Guangdong Hengrui Pharmaceutical Co., Ltd
Healthy
A Study in Healthy People to Measure How Different Doses of Verducatib Affect the Heart
The main objective of this trial is to evaluate the effects of verducatib in the range of therapeutic to supra-therapeutic exposures on the QT/QTc-interval and other ECG parameters
- Trial name
- NCT07760246
- Testing
- Verducatib, Moxifloxacin
- Where
- Germany
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Acanthamoeba Keratitis, Fungal Keratitis
Rose Bengal Electromagnetic Activation With Green Light for Infection Reduction
Rose Bengal Electromagnetic Activation with Green light for Infection Reduction (REAGIR ) is an international, randomized, doubled masked, clinical trial.
- Trial name
- REAGIR (NCT05110001)
- Testing
- Moxifloxacin Ophthalmic, Chlorhexidine Gluconate, Natamycin
- Where
- 2 sites in Brazil, India
- Volunteers
- 330 people
- Sponsor
- University of California, San Francisco